Review Article

Hematopoietic Stem Cell Development, Niches, and Signaling Pathways

Kamonnaree Chotinantakul\(^1,2\) and Wilairat Leeanansaksiri\(^1,2\)

\(^1\)Stem Cell Therapy and Transplantation Research Group, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand
\(^2\)School of Microbiology, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand

Correspondence should be addressed to Wilairat Leeanansaksiri, wilairat@g.sut.ac.th

Received 9 March 2012; Revised 30 May 2012; Accepted 13 June 2012

Academic Editor: Amanda C. LaRue

Copyright © 2012 K. Chotinantakul and W. Leeanansaksiri. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hematopoietic stem cells (HSCs) play a key role in hematopoietic system that functions mainly in homeostasis and immune response. HSC transplantation has been applied for the treatment of several diseases. However, HSCs persist in the small quantity within the body, mostly in the quiescent state. Understanding the basic knowledge of HSCs is useful for stem cell biology research and therapeutic medicine development. Thus, this paper emphasizes on HSC origin, source, niches, and signaling pathways which support HSC maintenance and balance between self-renewal and proliferation which will be useful for the advancement of HSC expansion and transplantation in the future.

1. Introduction

Hematopoietic stem cells (HSC) are adult stem cells that contain the potentiality in self-renew and differentiation into specialized blood cells that function in some biological activities: control homeostasis balance, immune function, and response to microorganisms and inflammation. HSCs can also differentiate into other specialized cell or so called plasticity such as adipocytes [1], cardiomyocytes [2], endothelial cells [3], fibroblasts/myofibroblasts [4], liver cells [5, 6], osteochondrocytes [7, 8], and pancreatic cells [9]. Most HSCs are in quiescent state within the niches that maintain HSC pool and will respond to the signals after the balance of blood cells or HSC pool is disturbed from either intrinsic or extrinsic stimuli.

In addition, HSCs have been studied extensively, especially, for the therapeutic purposes in the treatment of blood diseases, inherited blood disorders, and autoimmune diseases. Nonetheless, advanced development in this field needs knowledge in the biological studies as a background in performing strategy and maintaining of HSCs. Thus, HSC source, origin, niches for HSC pool, and signaling pathways, essential for the regulation of HSCs, will be discussed in this review.

2. HSCs Origin and Development

In the hematopoietic system, the discovery of HSCs has shed the light on stem cell biology studies including connection to other adult stem cells through the basic concepts of differentiation, multipotentiality, and self-renewal. In the early period of those discoveries, lethally irradiated animals were found to be rescued by spleen cells or marrow cells [17, 18]. After mouse bone marrow cells were transplanted into irradiated mice, the clonogenic mixed colony of hematopoietic cells (often composed of granulocyte/megakaryocyte and erythroid precursors) were formed within the spleen, which these colonies were then termed colony-forming unit spleen (CFU-S) [19]. Some colonies of primary CFU-S could reconstitute hematopoietic system in the secondary irradiated mice after receiving transplantation [20]. Initially, CFU-S was first proposed that it may be differentiated from HSC, but subsequently, CFU-S was demonstrated to be originated from more committed progenitor cells [21]. The discovery by Till and McCulloch embarked on a new journey toward many investigations to clarify HSC biology, functional characterization, purify, cultivation, and other stem cells research.
Hematopoiesis and HSC development are the key role to improve efficient HSC expansion for the transplantations. Embryogenesis study has been performed to identify HSC origin and activity from various anatomical sites of several kinds of animals such as zebrafish, chicken, and mouse including human embryos model have been emerging. Initially, Moore and Metcalf showed that hematopoietic cells in the yolk sac could generate hematopoietic progenitors that restricted to only erythroid and myeloid lineages [22]. Moreover, the Runx1 (transcription factor for the onset of definitive hematopoiesis) was first identified to express at embryonic day 7.5 (E7.5) in the yolk sac, the chorionic mesoderm, and parts of allantoic mesoderm [23]. However, HSCs found in the yolk sac lacked the definitive hematopoietic stem cells which did not show long-term hematopoietic reconstitution activity in mouse embryo prior to E11.5 [24]. On the other hand, long-term repopulating HSCs (LT-HSCs) were shown to increase largely in the aorta-gonad mesonephros (AGMs) region of the mouse embryo including the serially transplantable irradiated mice, suggesting that AGM region is the first site for HSCs detection [24, 25]. Vitelline and umbilical arteries were also endowed with hematopoietic potential [26]. The presence of HSC phenotype in the embryo was supported by the evidence that a high number of nonerythroid progenitors with high-proliferative potential was observed from which the liver rudiment has been removed [27]. A dense population of CD34+ cells adhering to the ventral side of the aortic endothelium within the embryonic compartment was shown to display a cell-surface and molecular phenotype of primitive hematopoietic progenitors (CD45+, CD34+, CD31+, CD38−, negative for lineage markers, GATA-2+, GATA-3+, c-myb+, SCL/TAL1+, c-kit+, flk-1/KDR+) [28, 29]. Moreover, the autonomously emergence of myelolymphoid lineage from progenitors was found in splanchnopleural mesoderm and derived aorta within the human embryo proper, while restricted progenitors were generated in the yolk sac [30]. Altogether, AGM region in the embryo is suggested as the source of definitive hematopoiesis as the generation occurs between E10.5 and E12.0 with the enhance activity of HSC after mid-day 11 of gestation [10, 31–33]. Even though, the main source of fetal hematopoiesis was considered in AGM including vitelline and umbilical arteries, the question is raised whether the rare population produced in those regions would be enough for the distribution into fetal liver for alternative development of enormous HSCs before the transition of hematopoiesis continues to occur in the fetal thymus and bone marrow in postnatal life. Recently, the placenta, an extraembryonic organ, has been considered as the other hematopoietic organ for de novo hematopoiesis [34, 35]. This may be due to the physiology of the placenta containing highly vascularized blood vessels, and cytokines and growth factors rich environment for proper microenvironment of hematopoiesis and development [36]. Additionally, privilege site within the placenta may hide the HSCs from the promoting signal into differentiation stage. However, there is no experimental evidence to support that HSCs are generated de novo in the extraembryonic tissues. Therefore, future works will be needed to elucidate this enigma. Summarization of the source of blood cells during gestation through adult life has been elucidated in Figure 1.

The origin of HSC in the placenta is being questioned. Understanding how the placenta develops might be useful to define the source and the niches supporting HSC development. Mouse and human placentas are anatomically similar and its genes have analogous identity [37, 38]. The placenta is formed from trophectoderm, mesodermal tissues, chorionic mesoderm, and allantois (Figure 2) [39]. At E8.5 of mouse gestation, the allantois develops and fuses with chorionic mesoderm through its distal part generating the chorioallantoic mesenchyme in the chorionic plate and continuing to form the fetal vascular compartment of the placental labyrinth, while the proximal part becomes the umbilical cord [11].

The umbilical cord (a constitution of the fetal arteries and veins that inserted within chorionic plate of the placenta) is attached to the center of fetal surface for uteroplacenta circulation through maternal blood. Maternal blood passes through the placenta from uterine arteries to spiral arteries in the maternal decidua. Thereafter, the maternal blood percolates through the villous tree in humans (or the

| Duration | Source          |
|---------|----------------|
| E7      | Yolk sac       |
| E8.5–10.5| Placenta       |
| E10.5   | AGM            |
| E11     | Liver          |
| E16     | Bone Marrow    |
| Adult   |                |

Figure 1: Source of blood cells during gestation through after birth. Intraembryonic yolk sac is the first site of blood cells observation at around E7.0–E7.5. The de novo hematopoiesis in the placenta and AGM occurs at nearly similar wave of gestation (around E8.5–E10.5) before it circulates into fetal liver where there is the large HSC pool during gestation. At around E16.5, the HSCs migrate and reside within the bone marrow which finally becomes the source of HSC in adult life (adapted from [10]).
labyrinth in mice) known as chorionic villi which created and lined by fetal trophoblast cells [37, 39]. The inner core of the chorionic villi consists of allantoic mesenchyme and vasculature which is continuous with that of the umbilical cord. The chorioallantoic vasculature connects the placenta via the dorsal aorta and fetal liver through the umbilical cord vessels. These regions are localized by an equally dense network of fetal capillaries where the fetomaternal exchange occurs [37].

Because of the mesoderm layer gives rise to all blood cells, the chorionic and allantoic mesoderms are considered as the origin of HSC in the placenta. This can be explained by the observation that hematopoietic potential emerging from both tissues and has been identified with myelopoietic potential [40]. In addition, hematopoietic cells (CD34+CD45+) collected from placental villi stroma and highly expression of CD45+ cells that appear to be budding from the vasculature have been found from human placenta during midgestation [35]. Moreover, cells harvested from term human placenta vessels and tissues could generate human hematopoietic repopulation of nonobese diabetic (NOD)-SCID mice, which harbored and/or amplified in vascular labyrinth placenta niche [35]. These observations imply that the placenta is the HSC source along with umbilical cord blood. At E10.5, first HSC emerge in the dorsal aorta before the onset of heart beat where the circulation has not been formed. One study showed that in the absence of heat beat in Ncx1 (the sodium and calcium exchange pump1) knockout embryos, the HSC development was verified to initiate in the placental vasculature [41].

Additionally, multilineage hematopoietic potential could be obtained from placentas of Ncx1 knockout embryos. Thus, within the extraembryonic tissues, fetal HSCs were observed in placenta, vitelline, and umbilical arteries.

The true origin of HSC in the intraembryonic hematopoiesis remains controversial. One of the main hypotheses is hemangioblasts or hemogenic endothelial while the alternative model is mesodermal precursors. The blood islands originated in the yolk sac are derived from mesodermal cell aggregates, which contain the ability to differentiate into both hematopoietic and endothelial cells. The common precursor by those lineages is suggested to be so called the hemangioblast [42]. Hematopoietic phenotype originated from hemogenic endothelium has been found in avian and mouse during ontogeny [43, 44]. Imaging and cell-tracking study explored that hemogenic endothelial cells could give rise to hematopoietic cells [45]. By time-lapse imaging study in single-cell mouse mesodermal cells demonstrated that it could generate endothelial sheet colonies and some colonies developed the hematopoietic morphology that upregulating the blood-specific proteins CD45, CD41, and CD11b and losing their intact morphology. Recently, this evidence has been supported by the observation on time-lapse confocal imaging from live mouse aorta showing that HSCs (Sca+, c-kit+, CD41+) could emerge directly from ventral aortic endothelial cells [46]. Moreover, Oberlin and colleagues proved that the origin of adult bone marrow HSCs which most of them derived were from the vascular endothelial-cadherin ancestor [47]. Taken together, these studies pinpoint the evidence that definitive hematopoietic stem and progenitor cells emerge from the hemogenic endothelium at the AGM region.

3. HSC Niches

Homing of HSC from other definitive hematopoiesis to fetal bone marrow is thought to involve some signaling factors such as stromal derived-factor-1 (SDF-1 or CXCL12)/chemokine C-X-C receptor 4 (CXCR4) axis [48, 49]. Soluble factors are not only mediated in fetal bone marrow but also in adult bone marrow to maintain HSC
in undifferentiated state and regulate HSC in proliferative and cell adhesion [64]. In addition, HSCs were found to adhere with spindle-shaped N-cadherin+ osteoblastic (SNO) cells which are a subpopulation of osteoblasts [65]. BMP receptor type IA mutant mice have been shown to increase in the number of SNO cells that correlated to an increase in HSC number [65]. Consistently, green fluorescent protein-positive (GFP+) HSCs derived from Col2.3-GFP+ transgenic mouse were found to attach to SNO cells but not all GFP+ HSCs were in contact with SNO cells showing that N-cadherin– component might be the other niche for HSCs [54]. Cumulatively, osteoblasts and SNO cells are suggested as the niche for hematopoietic stem and progenitor cells where this microenvironment termed “Endosteal niche.”

Some observations have suggested that another niche, vascular niche, might involve in HSC maintenance within the bone marrow. Studies in osteoblast depletion demonstrated that there was a loss of B lymphopoiesis but not immediately loss of HSC number [66, 67] and few bone-marrow HSCs (CD150+CD48–CD41– lineage−) were localized to the endosteum [68]. Mice model defective in osteoblast function conferred no changes in LT-reconstitution function of HSCs [69]. Additionally, the loss of N-cadherin did not any effect on HSC maintenance and hematopoiesis [70]. Most HSCs in the bone marrow have been observed to reside in the sinusoid, where fenestrated endothelium persists and allows blood flow for an exchange of blood cells and small molecules. Taken together, the vascular niche is suggested as the other niche for HSC maintenance [68]. Bone-marrow endothelial cells have been proposed to play a role in HSC controlling within vascular niche. Primary CD31+ microvascular endothelial cells can restore hematopoiesis in mice when they receive bone-marrow lethal doses of irradiation [71]. Study by a group of Salter shows a consistent observation that endothelial progenitor cells injected in total body irradiated mice can stimulate HSC reconstitution and hematologic recovery [72]. Furthermore, selective activation of Akt in endothelial cells produced angiocrine factors mediated in the reconstitution, expansion, and maintenance of HSCs [73]. Nonetheless, constitutively activation of Akt, a binding ligand of phosphoinositide 3 in the phosphoinositide 3-kinase pathway, impaired engraftment ability and preferable generated leukemia in mice [74]. sinusoidal endothelial cells are essential for engraftment of hematopoietic stem and progenitor cells (HSPCs) and restoration of hematopoiesis after myeloablation [75]. Angiocrine factors, such as Notch ligands, released by endothelial cells in vivo contributed to the replenishment of the LT-HSC pool and resulted in reconstitution of hematopoiesis [76]. Altogether, vascular niche containing endothelial cells is suggested as the major HSC pool and maintenance conferring proliferation and differentiation selection.

Additionally, Sugiyama and colleagues demonstrated that reticular cells located around the sinusoid endothelium could produce stromal cell-derived factor 1 (SDF-1, aka CXCL12) mediated in HSC niche [77]. These cells have been named CXCL12 abundant reticular cells (CAR cells). This study showed that almost all HSCs were found in contact with CAR cells and all HSCs allocated at endosteum were also found to be in contact with CAR cells, suggesting that these cells play...
a crucial role in HSC niches by homing HSCs in both vascular and endosteal niches [77]. CXCL12/CXCR4 signaling is essential in maintaining the HSC pool, development of B cells and plasmacytoid dendritic cells [78–81]. Moreover, short-term ablation of CAR cells resulted in the impairment of adipogenic and osteogenic differentiation. Thus, CAR cells are suggested as the adipo-osteogenic progenitors [82]. Study in CAR cell-depleted mice demonstrated that HSCs were reduced in number and cell size, which were more quiescent and highly expressed early myeloid selector genes [82]. CAR cells were suggested to coincide with CD146+ stromal progenitors that express CXCL12 and Ang-1. CD146+ cells could generate osteoblast that form bone and could function as skeletal progenitor cells [83]. Taken together, CAR cells provide or generate the hematopoietic microenvironment that link to the hematopoietic regulation in both vascular and endosteal niches.

4. Hierarchy of Human Hematopoiesis

Based on the study of molecular marker expression by flow cytometry analysis has led the identification of each blood cell subpopulations in terms of their biology and potential when combined with other functional assays. As a result, schematic demonstration of hematopoietic hierarchy has been proposed (Figure 4) [13]. The origin of all blood cell in hematopoietic system is believed to be derived from HSCs that contain self-renewal capacity and give rise to multipotent progenitors (MPPs) which lose self-renewal potential but remain fully differentiate into all multilineages. MPPs further give rise to oligopotent progenitors which are common lymphoid and myeloid progenitors (CLPs and CMPs, resp.). All these oligopotent progenitors differentiate into their restricted lineage commitment: (1) CMPs advance to megakaryocyte/erythrocyte progenitors (MEPs), granulocyte/macrophage progenitors (GMPs), and dendritic cell (DC) progenitors, (2) CLPs give rise to T cell progenitors, B cell progenitors, NK cell progenitors and DC progenitors. Notably, DC progenitors (CD8α+ DC, CD8α– DC, and plasmacytoid DC) could be derived from both CMPs and CLPs [84–86].

Among the isolation and characterization of HSCs and progenitors, CD34 molecule is the first widely chosen for the study by several researchers. CD34 is comprised in the CD34 family of cell-surface transmembrane proteins together with podocalyxin and endoglycan [87–89]. CD34 expression on blood cells is about 0.1–4.9% in human cord blood, bone marrow, and peripheral blood [90–92]. The first candidate human HSCs was a population of cells
Expressing CD34⁺CD90⁺(Thy-1)Lin⁻ which could give rise to T and B lymphocytes and myeloid activities in both *in vitro* and *in vivo* human fetal thymus transplanted into SCID mice while some subset of CD34⁺, CD90⁻, Lin⁻ lacked of multipotent progenitors [93]. Further isolation of HSCs was based on the expression of CD38 [94, 95] and CD45RA [96]. This data could be concluded that Lin⁻CD34⁺CD38⁻CD90⁻CD45RA⁻ population enriches for human HSCs and the candidate human MPP fraction of multipotency with an incomplete self-renewal capacity is enriched in Lin⁻CD34⁺CD38⁻CD90⁻CD45RA⁻ population [97]. However, recently observation using HSC xenograft assay in NOD-SCID-IL2Rgc⁻/⁻ (NSG) mice has shown that both Lin⁻CD34⁺CD38⁺CD90⁻CD45RA⁻ and Lin⁻CD34⁺CD38⁻CD90⁺CD45RA⁻ contain LT repopulating activity in secondary recipients with different frequency [98]. Taken together, these results demonstrate that human HSCs are enriched in the Lin⁻CD34⁺CD38⁻CD90⁻⁻/⁻CD45RA⁻ Rholo population of hematopoietic cells (Figure 4).

### 5. Signaling Pathways in Self-Renewal and Maintenance of HSCs

The balance that controls between self-renewal and differentiation (or cell fate decision) of HSCs in the bone marrow is mediated by several factors. There are a number of animal models promoting the concept that the niches inside bone marrow provide the maintenance and regulation of HSCs by some microenvironmental-dependent signals.

Most HSCs are in quiescent state (i.e., in G0/G1 phase of the cell cycle) [99], however, when the hematopoietic cells disturbance occurs, hematopoiesis system will respond by shutting down or turning on the regulators mediated in the

| Figure 4: Hierarchy of hematopoiesis. The phenotypic cell surface marker of each population of mouse and human blood system is shown (modified from [13]). In the mouse hematopoiesis system, MPPs omit CMPs which directly give rise to MEPs unlike in the human system (dash line). CLP, common lymphoid progenitor; CMP, common myeloid progenitor; DC, dendritic cell; EP, erythrocyte progenitor; GMP, granulocyte/macrophage progenitor; GP, granulocyte progenitor; HSC, hematopoietic stem cell; MacP, macrophage progenitor; MEP, megakaryocyte/erythrocyte progenitor; Mkp, megakaryocyte progenitor; NK, natural killer; Lin, lineage markers.

| Mouse | Human |
|-------|-------|
| Lin⁻cKit⁺Sca1⁺Flk2⁻CD34⁺Slamf1⁺ | Self-renewal Lin⁻CD34⁺CD38⁻CD90⁺⁻/⁻CD45RA⁻ CD49f⁺Rholo |
| Multipotent progenitors | |
| Lin⁻cKit⁺Sca1⁺Flk2⁻CD34⁺Slamf1⁺ | Lin⁻CD34⁺CD38⁻CD90⁺⁻/⁻CD45RA⁻ CD49f⁺ |
| Lin⁻cKit⁺Sca1⁺Flk2⁻CD34⁺Slamf1⁺ | |
| Lin⁻cKit⁺Sca1⁺Flk2⁺CD34⁺Slamf1⁺ | |
| Oligopotent progenitors | |
| Lin⁻Flk2⁺IL7Ra⁺CD27⁺ | CLP Lin⁻CD34⁺CD38⁺CD10⁺ |
| Lin⁻cKit⁺Sca1⁻/⁻lowCD34⁻CD90⁻CD45RA⁻ | CMP Lin⁻CD34⁺CD38⁺CD10⁻ |
| Lin⁻cKit⁺Sca1⁻/⁻lowCD34⁻FcgR⁻ | MEP Lin⁻CD34⁺CD38⁺CD10⁺ |
| Lin⁻cKit⁺Sca1⁺CD34⁺FcgR⁺ | GMP Lin⁻CD34⁺CD38⁺CD10⁻ |
| Lin⁻cKit⁺Sca1⁺CD34⁺FcgR⁻ | |
| Lineage-restricted progenitors | |
| Mkp | EP |
| EP | GP |
| GP | MacP |
| MacP | Pro-DC |
| Pro-DC | Pro-B |
| Pro-B | Pro-T |
| Pro-T | Pro-NK |
| Mature effector cells | |
| Platelets | Erythrocyte |
| Erythrocyte | Granulocytes |
| Granulocytes | Macrophages |
| Macrophages | Dendritic cells |
| Dendritic cells | B-cells |
| B-cells | T-cells |
| T-cells | NK-cells |
regulations. Several pathways have been studied in relation to that circumstance which are SDF-1 (CXCL12)/CXCR4 signaling, BMP signaling, Mpl/Thrombopoietin (TPO) signaling, Tie2/Ang-1 signaling, hedgehog and Notch signaling, as well as Wingless (Wnt) signaling.

5.1. SDF-1 (CXCL12)/CXCR4 Signaling Pathway. Stromal cell-derived factor 1 (SDF-1) is constitutively expressed in several organs including lung, liver, skin, and bone marrow [100]. SDF-1 belongs to α-chemokines that functions as chemoattractant for both committed and primitive hematopoietic progenitors and regulates embryonic development including organ homeostasis [100]. There are two main splicing forms that have been identified, SDF-1α and SDF-1β, which ubiquitously expressed with highest levels detected in liver, pancreas, and spleen [101]. Additionally, another variant form, SDF-γ, has been characterized in the nervous system [102]. Subsequently, SDF-1β, SDF-1ε, and SDF-φ have been identified with highly expression in pancreases and lower levels detection in heart, kidney, liver, and spleen [103]. SDF-1 counteracts with its cognate receptor, CXCR4 that expresses widely in numerous tissues including hematopoietic and endothelial cells to stimulate the physiological processes. SDF-1/CXCR4 signaling plays a critical role during embryonic development by regulating B-cell lymphopoiesis, myelopoiesis in bone marrow and heart ventricular septum formation [104–106]. In addition, SDF-1 has been shown to be mediated in the recruitment of endothelial progenitor cells (EPCs) from the bone marrow through a CXCR4 dependent mechanism suggesting the functional role in vasculogenesis in which EPCs could form blood vessels [107]. A number of observations demonstrated that there was an increase in SDF-1 expression the ischemic sites [108, 109]. More evidence demonstrated that locally injection of SDF-1 augmented vasculogenesis and subsequently contributed to ischemic neovascularization in vivo by promoting EPC recruitment in ischemic tissues [110]. Recently, Liu and colleagues have shown that signal of SDF-1/CXCR4 together with CXCR7 can increase the mobilization and paracrine actions of mesenchymal stem cells (MSCs) ischemic kidneys under hypoxia condition [111]. Moreover, SDF-1/CXCR4 not only plays a role in HSC maintenance but also regulates HSC attachment within the niche. The mechanism mediated in this regulation was found to be activated through matrix metalloproteinase-9 that mediated in the releasing of soluble Kit-ligand [112]. Inactivation or deletion of CXCR4 in mice resulted in HSC pool reduction and hyperproliferation responsive to HSC deflections [77, 78]. Tseng and colleagues also confirmed the role of SDF-1 in HSC maintenance by demonstrating that a conditional SDF-1-deficient mice conferred an impairment in HSC quiescence and endosteal niche localization [113].

5.2. BMP Signaling Pathway. Bone morphogenic proteins (BMPs) are a group of growth factors that belongs to a TGF-β family member [114]. BMPs are mainly produced by osteoclasts in HSC niche [115]. During embryogenesis, BMP-4 regulates hematopoietic lineage commitment from mesodermal cell, while HSC number and function within bone marrow niche is controlled by Bmp-4 during adult life [116, 117]. Knowledge of BMP signaling and receptor related adult HSC within bone marrow has been studied in a small number and is elusive. BMP signaling impairment displayed an increase in the niche size, leading to the enhancement in the number of HSCs [65]. Differential response of HSC to soluble BMPs observed by a group of Bhatia showed that higher concentrations of BMP-2, BMP-4 and BMP-7 maintained human CB HSCs in vitro while at lower concentrations of BMP-4-induced proliferation and differentiation of HSCs [118].

5.3. c-Mpl/TPO Signaling Pathway. c-Mpl and its ligand, thrombopoietin (TPO), are known to regulate megakaryopoiesis [119]. c-Mpl receptor is expressed mainly on HSCs, with a lesser extent on megakaryocytic progenitors, megakaryocytes and platelets [120]. Various tissues expressing c-Mpl are mediated in hematopoiesis, including bone marrow, spleen, and fetal liver [14]. Based on the crystallographic EPO receptor study and its analogy to the TPO receptor have led to the postulation that TPO initiates the signal transduction by binding to the c-Mpl at the distal part, which in turn a homodimer of c-Mpl becomes active [15]. Consequently, Janus kinase 2 (JAK2) can phosphorylate tyrosine residues within the receptor itself which at least two tyrosine residues, Tyr625 and Tyr630, are phosphorylated on c-Mpl [15, 122], thereby stimulating the downstream cascade STATs, PI3K, the mitogen-activated protein kinases (MAPKs), and extracellular signal regulated kinases-1 and -2 (Figure5) [123, 124]. c-Mpl/TPO signaling involved in postnatal steady-state HSC maintenance and cell-cycle progression at the endosteal surface [125, 126]. Mpl-expressed LT-HSCs were found in correlation to cell cycle quiescence and that was closely associated with TPO-producing osteoblastic cells in the bone marrow [125]. Additionally, the inhibitory adaptor protein Lnk was suggested as a negative regulator of JAK2 in HSCs following TPO stimulation, in which HSC quiescence and self-renewal controls were predominantly through Mpl [127]. Therefore, TPO/Mpl/JAK2/Lnk pathway can be concluded as a gatekeeper for HSC quiescence. Recently, TPO knock-in RAG2−/−γc−/− mice has been shown to improve human engraftment in the bone marrow and maintenance of HSPCs pool by serial transplantation [128]. Taken together, TPO has an important function in maintenance and self-renewal of HSCs.

5.4. Tie2/Ang-1 Signaling. Angiopoietin-1 (Ang-1) is the ligand of Tie2, a receptor tyrosine kinase, which expresses predominantly on osteoblastic cells in endosteum [59] and in MSCs [83]. Interaction of Tie2 with its ligand, Ang-1, resulted in tightly adhesion of HSCs to the niche and become more quiescence [59]. Moreover, Ang-1 conferred the maintenance of LT-HSCs while Ang-2 did not antagonize the effects of Ang-1 on gene expression, Akt (aka protein B) phosphorylation [129].
5.5. Hedgehog Signaling Pathway. Hedgehog (Hh) is proposed as a negative regulator of the HSC quiescence [130]. Hh ligand binds to the transmembrane receptor Patched (Ptc) and subsequently allows the signaling function of a second transmembrane protein, Smoothened (Smo), essentially for the Hh signal to be active. Trowbridge and colleagues demonstrated that constitutive activation of the Hh signaling pathway in Ptc heterozygous (Ptc-1+/−) mice resulted in induction of cell cycling and expansion of primitive bone marrow hematopoietic cells [130]. To support this hypothesis, deletion of Smo in the in utero of transgenic mice was performed and the result demonstrated that there was an impaired stem cell self-renewal and the inhibition in engraftment activity of HSCs [131]. Furthermore, the common downstream positive effector of Hg signaling, Glil, has been shown to play a critical role in normal and stress hematopoiesis [132]. Nonetheless, the discrepancies on Hg role in hematopoiesis were shown in some studies claiming that the conditional loss of Smo within adult HSCs is dispensable for hematopoiesis [133, 134]. These conflicts might be due to the difference of the mice model and conditional system used to impair Hg signaling.

5.6. Notch Signaling Pathway. Notch signaling plays a key role in several fundamental functions including proliferation, differentiation and cell fate decision [135, 136]. Four notch receptors (Notch 1–4) and five ligands (Jagged1-2 and Delta-like 1, 3, and 4) have been identified in mammals [137]. Cells expressing Notch ligands or engineered immobilized Notch ligands could maintain or enhance HSC self-renewal in the culture [138, 139]. Some investigations demonstrated that there were an impaired HSCs differentiation both in vitro [140, 141] and in vivo [139, 141] studies following interaction of Notch receptors and Notch ligands. Transcription factor act upstream of the Notch signaling cascade, Hes2, was shown to be essential in HSCs formation in zebrafish embryos when hes2 expression was knockdown, whereas HSC formation could be rescued by the activation of Notch signal [142]. One study showed that an increase in in vitro maintenance of hematopoietic functions and repopulating potential on osteoblasts and Lineage− Sca-1+CD117+ (LSK) cells coculture was mediated by the up-regulation of Notch signal (Notch2, Jagged1 and 2, Delta1 and 4, Hes1 and 5, and Deltex) [58]. Taken together, these studies support the role of Notch signaling mediated in HSC hematopoiesis and maintenance. In the contrary,
some investigations proposed that Notch signaling was not important for HSC self-renewal and maintenance [143, 144]. Inactivation of Notch1 and Jagged1 in bone marrow progenitors and bone marrow stroma, respectively, did not impair HSC maintenance and reconstitution [144]. The inhibition of Notch1–4 signaling via a developed dominant-negative Mastermind-like1 construct was transfected into LSK and demonstrated similar result of LT reconstitution in bone marrow compared to LSK control, except for T-cells [143]. Nevertheless, the study by Kim and colleague explored the important of Notch in normal hematopoiesis [145]. Mind bomb (Mib)-1, which regulates the endocytosis of Notch ligands and activation, was inactivated in mice leading to myeloproliferative disease (MPD). Surprisingly, when transplanted with wild-type bone marrow cells into the Mib1-null microenvironment, it results in a de novo MPD. The MPD progression was suppressed by transplantable Notch activating cells, suggesting that MPD develops from the nonhematopoietic microenvironmental cells with defective Notch signaling. Therefore, Notch signaling is indeed required for normal hematopoiesis. Santaguida and colleague developed Juntß-decient mice which resulted in impairment of Notch and transforming growth factor-ß (TGF-ß) signaling, in part via the transcriptional regulation of Hes1 [146]. This study showed an increase in LT-HSCs proliferation and differentiation without impairing their self-renewal in vivo, suggesting that LT-HSC proliferation rate is not exclusively compelling to self-renewal activity and maintenance of HSC in the BM niches.

5.7. Wnt Signaling Pathway: Notch signaling is involved in the cross-talk with other pathways particularly Wnt signaling not only in hematopoesis [147] but also in other cellular development [136, 148–151]. In addition, Wnt signaling pathway is mediated in the regulation of stem cell fate and maintenance of mouse ESCs and human ESCs in undifferentiated state [152, 153]. There are at least two independent pathway comprised in Wnt signaling: canonical Wnt and noncanonical Wnt signaling pathways. The canonical Wnt signal interacts with Frizzled (Fz) receptors and single-pass co-receptors LDL-receptor-related proteins 5 and 6 (LRP 5 and 6). The Fz protein contains a conserved motif, a cysteine rich domain (CRD) located on the extracellular domain that binds to multiple Wnts with a high affinity (Figure 6) [154]. Specifically, Dishevelled (DVL) is phosphorylated by casein kinase Ie (CKIε), which then binds typically to FRAT and confers the assembly between Fz to DVL (Fz-DVL complex) and LRP5/6 to AXIN and FRAT (LRP5/6-AXIN-FRAT complex) [155, 156]. After that, ß-catenin is stabilized and released from phosphorylation by CKIß and GSKßß. Then, ß-catenin forms the complex with T-cell factor/lymphoid enhancer binding factor (TCF/LEF) family transcription factors and also with Legless family docking proteins (BCL9 and BCL9L) associated with PYGO family coactivators for stabilization and nuclear accumulation [157–159]. Typically, the downstream effectors for transcriptional activation target genes are FGFB20, DKK1, WISP1, MYC, and CCND1 [160–163]. In the absence of Wnt, ß-catenin is stabilized by phosphorylation of CKIß and glycogen synthase kinase 3ß (GSK 3ß), which then resulted in a formation of a destruction complex facilitating by ß-catenin-APC-AXIN that is polyubiquitinated by ßTRCP1 or ßTRCP2 complex for the degradation by proteasome [16, 159].

In the second pathway, “noncanonical Wnt signal” exerts the independent ß-catenin signaling. The Wnt subfamily members, for example, Wnt5a binds to the Frizzled receptor, stimulates downstream intracellular signaling, resulting in an increase in intracellular Ca2+, and then activates protein kinase C and calmodulin-dependent kinase [159]. The cross-talk between Notch and Wnt signaling pathways was found in the stabilizing ß-catenin on bone-marrow stroma cells that promoted maintaining and self-renewal of HSCs [164]. Moreover, the induction of Jagged1 and delta-like 1 was observed in Wnt/ß-catenin-activated bone-marrow stroma or in bone-marrow stroma cultured with Wnt3a-conditioned medium [164]. Mice lacking Wnt3a resulted in prenatal death [165]. Moreover, Wnt3a deficiency reduced the number of HSCs in fetal liver and impaired the repopulating activity in vivo [165]. However, the exact role of Wnt signaling pathway in regulation of HSCs remains a controversy. Some studies demonstrated that constitutive activation of Wnt/ß-catenin in transgenic mice resulting in the multilineage differentiation block and loss of repopulating stem cell activity due to the induction of quiescent stem cells entering into cell cycle and arresting their differentiation [166, 167]. In contrast to previous works, the administration of an inhibitor of GSK-3ß in vivo displayed the enhancement in the recovery of hematopoietic cells for neutrophil and megakaryocytes lineages as well as primitive LSK cell population together with the upregulation of Wnt, Notch, and Hedgehog genes [168].

Furthermore, inhibition of Wnt signaling in HSCs by overexpression of the paninhibitor of canonical Wnt signaling, Dickkopf1 (Dkk1), resulted in the induction of cell cycling and reduction in repopulating ability in transplanted induction mice [169]. When the inhibitor of GSK-3ß, 6-bromoiridiniburn 3ß-oxime was used to treat CB-CD34+ cells, cell cycle progression was delayed including promoted engrainment of ex vivo-expanded HSCs [170]. Cumulatively, these studies suggest the positive regulatory role of Wnt/ß-catenin signal on the proliferative or repopulating activity of HSCs. 12/15-lipoxygenase-mediated unsaturated fatty acid metabolism has been implicated in canonical Wnt-related signaling in the maintenance of LT-HSC quiescence and number [171]. Taken together, the canonical Wnt signal is mediated in the regulation of HSC function by maintaining quiescence and balance in proliferation.

6. Concluding Remarks

HSCs have been studied extensively for HSC source, hematopoiesis, biological functions, and signaling pathways related to the maintenance and regulation of HSCs. Advance researches such as imaging system clearly provide useful information on tracking the HSC origin, pool, and transplantation outcome in the mouse models. The observation
Figure 6: A canonical Wnt signaling pathway. In the presence of Wnt, the signals are transduced through Frizzled family receptors and LRP5/LRP6 coreceptor to the β-catenin signaling cascade which then stabilize hypophosphorylated β-catenin and interact with TCF/LEF, Legless and PYGO for target gene activations. MARK and CKIε are the positive regulators of canonical Wnt pathway, while APC, AXIN1, AXIN2, CKIα, NKD1, NKD2, βTRCP1, βTRCP2, and ANKRD6 are negative regulators. In the absence of Wnt, β-catenin-forming complex with AXIN and APC is phosphorylated, leading to be a target for ubiquitination and degradation by proteasome (adapted from [16]).

of molecular mechanisms downstream the signaling cascade of self-renewing and proliferation of HSCs will also provide the knowledge through the new discovery in the treatment of diseases including the development in the performing a large scale preparation of HSCs for clinical transplantation. In addition, the signaling pathways will also provide understanding insight into the cancer stem cells which are now challenging scientists to explore their possible strategy for the treatments.

References

[1] Y. Sera, A. C. LaRue, O. Moussa et al., “Hematopoietic stem cell origin of adipocytes,” Experimental Hematology, vol. 37, no. 9, pp. 1108.e4–1120.e4, 2009.
[2] M. Pozzobon, S. Bollini, L. Iop et al., “Human bone marrow-derived CD133+ cells delivered to a collagen patch on cryoinjured rat heart promote angiogenesis and arteriogenesis,” Cell Transplantation, vol. 19, no. 10, pp. 1247–1260, 2010.
[3] N. Elkhalif, H. El Baz, O. Hamman et al., “CD133+ human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis,” Acta Pathologica, Microbiologica et Immunologica, vol. 119, no. 1, pp. 66–75, 2011.
[4] Y. Ebihara, M. Masuya, A. C. LaRue et al., “Hematopoietic origins of fibroblasts: II. In vitro studies of fibroblasts, CFU-F, and fibrocytes,” Experimental Hematology, vol. 34, no. 2, pp. 219–229, 2006.
[5] S. Khurana and A. Mukhopadhyay, “In vitro transdifferentiation of adult hematopoietic stem cells: an alternative source of engraftable hepatocytes,” Journal of Hepatology, vol. 49, no. 6, pp. 998–1007, 2008.
[6] S. Sellamuthu, R. Manikandan, R. Thiagarajan et al., “In vitro trans-differentiation of human umbilical cord derived hematopoietic stem cells into hepatocyte like cells using combination of growth factors for cell based therapy,” Cytotechnology, vol. 63, no. 3, pp. 259–268, 2011.
[7] M. Dominici, C. Pritchard, J. E. Garlits, T. J. Hofmann, D. A. Persons, and E. M. Horwitz, “Hematopoietic cells and osteoblasts are derived from a common marrow progenitor after bone marrow transplantation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 32, pp. 11761–11766, 2004.
[8] M. Mehrotra, M. Rosol, M. Ogawa, and A. C. LaRue, “Amelioration of a mouse model of osteogenesis imperfecta with hematopoietic stem cell transplantation: microcomputed tomography studies,” Experimental Hematology, vol. 38, no. 7, pp. 593–602, 2010.
[9] H. Minamiguchi, F. Ishikawa, P. A. Fleming et al., “Transplanted human cord blood cells generate amylase-producing
pancreatic acinar cells in engrafted mice,” *Pancreas*, vol. 36, no. 2, pp. e30–e35, 2008.

[10] S. Coskun and K. K. Hirschi, “Establishment and regulation of the HSC niche: roles of osteoblastic and vascular compartments,” *Birth Defects Research C*, vol. 90, no. 4, pp. 229–242, 2010.

[11] C. Gekas, K. E. Rhodes, B. van Handel, A. Chhabra, M. Ueno, and H. K. A. Mikkola, “Hematopoietic stem cell development in the placenta,” *International Journal of Developmental Biology*, vol. 54, no. 6-7, pp. 1089–1098, 2010.

[12] T. Nagasawa, Y. Omatsu, and T. Sugiyama, “Control of hematopoietic stem cells by the bone marrow stromal niche: the role of reticular cells,” *Trends in Immunology*, vol. 32, no. 7, pp. 315–320, 2011.

[13] J. Seita and I. L. Weissman, “Hematopoietic stem cell: self-renewal versus differentiation,” *Wiley Interdisciplinary Reviews*, vol. 2, no. 6, pp. 640–653, 2010.

[14] F. S. Chou and J. C. Mulloy, “The thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis,” *Journal of Cellular Biochemistry*, vol. 112, no. 6, pp. 1491–1498, 2011.

[15] A. E. Geddis, “Megakaryopoiesis,” *Seminars in Hematology*, vol. 47, no. 3, pp. 212–219, 2010.

[16] M. Katoh and M. Katoh, “WNT signaling pathway and stem cell signaling network,” *Clinical Cancer Research*, vol. 13, no. 14, pp. 4042–4045, 2007.

[17] L. O. Jacobson, E. I. Simmons, E. K. Marks, and J. H. Eldredge, “Recovery from radiation injury,” *Science*, vol. 113, no. 2940, pp. 510–511, 1951.

[18] E. Lorenz, D. Uphoff, T. R. Reid, and E. Shelton, “Modification of irradiation injury in mice and guinea pigs by bone marrow injections,” *Journal of the National Cancer Institute*, vol. 12, no. 1, pp. 197–201, 1951.

[19] J. E. Till and E. A. Mc, “A direct measurement of the radiation sensitivity of normal mouse bone marrow cells,” *Radiation Research*, vol. 14, pp. 213–222, 1961.

[20] L. Siminovitch, E. A. McCulloch, and J. E. Till, “The distribution of colony-forming cells among spleen colonies,” *Journal of Cell Physiolog*, vol. 62, pp. 327–336, 1963.

[21] R. Schofield, “The relationship between the spleen colony-forming cell and the haemopoietic stem cell. A hypothesis,” *Blood Cells*, vol. 4, no. 1–2, pp. 7–25, 1978.

[22] M. A. Moore and D. Metcalf, “Ontogeny of the haemopoietic system: yolk sac origin of in vivo and in vitro colony forming cells in the developing mouse embryo,” *British Journal of Haematology*, vol. 18, no. 3, pp. 279–296, 1970.

[23] B. M. Zeigler, D. Sugiyama, M. Chen, Y. Guo, K. M. Downs, and N. A. Speck, “The allantois and chorion, when isolated before circulation or chorio-allantoic fusion, have hematopoietic potential,” *Development*, vol. 133, no. 21, pp. 4183–4192, 2006.

[24] A. Medvinsky and E. Dzierzak, “Definitive hematopoiesis is autonomously initiated by the AGM region,” *Cell*, vol. 86, no. 6, pp. 897–906, 1996.

[25] A. M. Müller, A. Medvinsky, J. Stroouboulis, F. Grosvold, and E. Dzierzak, “Development of hematopoietic stem cell activity in the mouse embryo,” *Immunity*, vol. 1, no. 4, pp. 291–301, 1994.

[26] M. F. T. R. de Bruijn, N. A. Speck, M. C. E. Peeters, and E. Dzierzak, “Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo,” *The EMBO Journal*, vol. 19, no. 11, pp. 2465–2474, 2000.

[27] A. Huyhn, M. Dommergues, B. Izac et al., “Characterization of hematopoietic progenitors from human yolk sacs and embryos,” *Blood*, vol. 86, no. 12, pp. 4474–4485, 1995.

[28] M. C. Labastie, F. Cortés, P. H. Roméo, C. Dulac, and B. Péault, “Molecular identity of hematopoietic precursor cells emerging in the human embryo,” *Blood*, vol. 92, no. 10, pp. 3624–3635, 1998.

[29] M. Tavian, L. Coulombel, D. Laton, H. S. Clemente, F. Dieterlen-Liévre, and B. Péault, “Aorta-associated CD34+ hematopoietic cells in the early human embryo,” *Blood*, vol. 87, no. 1, pp. 67–72, 1996.

[30] M. Tavian, C. Robin, L. Coulombel, and B. Péault, “The human embryo, but not its yolk sac, generates lympho-myeloid stem cells: mapping multipotent hematopoietic cell fate in intraembryonic mesoderm,” *Immunity*, vol. 15, no. 3, pp. 487–495, 2001.

[31] M. J. Chen, T. Yokomizo, B. M. Zeigler, E. Dzierzak, and N. A. Speck, “Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter,” *Nature*, vol. 457, no. 7231, pp. 887–891, 2009.

[32] M. F. T. R. De Bruijn, X. Ma, C. Robin, K. Ottersbach, M. J. Sanchez, and E. Dzierzak, “Hematopoietic stem cells localize to the endothelial cell layer in the midgestation mouse aorta,” *Immunity*, vol. 16, no. 5, pp. 673–683, 2002.

[33] E. Taylor, S. Taoudi, and A. Medvinsky, “Hematopoietic stem cell activity in the aorta-gonad-mesonephros region enhances after mid-day 11 of mouse development,” *International Journal of Developmental Biology*, vol. 54, no. 6-7, pp. 1055–1060, 2010.

[34] A. Bárcena, M. Kapidzic, M. O. Muench et al., “The human placenta is a hematopoietic organ during the embryonic and fetal periods of development,” *Developmental Biology*, vol. 327, no. 1, pp. 24–33, 2009.

[35] C. Robin, K. Bollerot, S. Mendes et al., “Human placenta is a potent hematopoietic niche containing hematopoietic stem and progenitor cells throughout development,” *Cell Stem Cell*, vol. 5, no. 4, pp. 385–395, 2009.

[36] J. C. Cross, “How to make a placenta: mechanisms of trophoblast cell differentiation in mice—a review,” *Placenta*, vol. 26, supplement 1, pp. 53–59, 2005.

[37] P. Georgiades, A. C. Ferguson-Smith, and G. J. Burton, “Comparative developmental anatomy of the murine and human definitive placentae,” *Placenta*, vol. 23, no. 1, pp. 3–19, 2002.

[38] B. Cox, M. Kotlyar, A. I. Evangelou et al., “Comparative systems biology of human and mouse as a tool to guide the modeling of human placental pathology,” *Molecular Systems Biology*, vol. 5, article 279, 2009.

[39] J. Rossant and J. C. Cross, “Placental development: lessons from mouse mutants,” *Nature Reviews Genetics*, vol. 2, no. 7, pp. 538–548, 2001.

[40] C. Corbel, J. Salain, P. Belo-Diabangouaya, and F. Dieterlen-Liévre, “Hematopoietic potential of the pre-fusion allantois,” *Developmental Biology*, vol. 301, no. 2, pp. 478–488, 2007.

[41] A. E. Geddis, “Megakaryopoiesis,” *Cell Stem Cell*, vol. 3, no. 2, pp. 252–263, 2008.

[42] P. D. F. Murray, “The development in vitro of the blood of the early chick embryo,” *Proceedings of the Royal Society*, vol. 111, no. 773, pp. 497–521, 1932.

[43] T. Jaffredo, R. Gautier, A. Eichmann, and F. Dieterlen-Liévre, “Intraaortic hematopoietic cells are derived from endothelial cells during ontogeny,” *Development*, vol. 125, no. 22, pp. 4575–4583, 1998.
[44] S. I. Nishikawa, S. Nishikawa, H. Kawamoto et al., “In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos,” *Immunology*, vol. 8, no. 6, pp. 761–769, 1998.

[45] H. M. Eikelen, S. I. Nishikawa, and T. Schroeder, “Continuous single-cell imaging of blood generation from haemogenic endothelium,” *Nature*, vol. 457, no. 7231, pp. 896–900, 2009.

[46] J. C. Boisset, W. Van Cappellen, C. Andreiu-Soler, N. Galiart, E. Dzierzak, and C. Robin, “In vivo imaging of hematopoietic cells emerging from the mouse aortic endothelium,” *Nature*, vol. 464, no. 7325, pp. 116–120, 2010.

[47] E. Oberlin, B. E. Hafny, L. Petit-Cocault, and M. Souyri, “Definitive human and mouse hematopoiesis originates from the embryonic endothelium: a new class of HSCs based on VE-cadherin expression,” *International Journal of Developmental Biology*, vol. 54, no. 6–7, pp. 1165–1173, 2010.

[48] T. Ara, K. Tokoyoda, T. Sugiyama, T. Egawa, K. Kawabata, and T. Nagasawa, “Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny,” *Immunity*, vol. 19, no. 2, pp. 257–267, 2003.

[49] Y. Guo, G. Hangoc, H. Bian, L. M. Pelus, and H. E. Brockmeyer, “SDF-1/CXCL12 enhances survival and chemotaxis of murine embryonic stem cells and production of primitive and definitive hematopoietic progenitor cells,” *Stem Cells*, vol. 23, no. 9, pp. 1324–1332, 2005.

[50] T. Xie and A. C. Spradling, “decapentaplegic is essential for the maintenance and division of germline stem cells in the Drosophila ovary,” *Cell*, vol. 94, no. 2, pp. 251–260, 1998.

[51] S. K. Nilsson, P. J. Simmons, and I. Bertocellio, “Hemopoietic stem cell engraftment,” *Experimental Hematology*, vol. 34, no. 2, pp. 123–129, 2006.

[52] S. Basu, N. T. Ray, S. J. Atkinson, and H. E. Brockmeyer, “Protein phosphatase 2A plays an important role in stromal cell-derived factor-1/CXCR chemokine ligand 12-mediated migration and adhesion of CD34+ cells,” *Journal of Immunology*, vol. 179, no. 5, pp. 3075–3085, 2007.

[53] C. Lo Celso, H. E. Fleming, J. W. Wu et al., “Live-animal tracking of individual hematopoietic stem/progenitor cells in their niche,” *Nature*, vol. 457, no. 7225, pp. 92–96, 2009.

[54] Y. Xie, T. Yin, W. Wiegraebe et al., “Detection of functional hematopoietic stem cell niche using real-time imaging,” *Nature*, vol. 457, no. 7225, pp. 97–101, 2009.

[55] Y. Jung, J. Song, Y. Shiozawa et al., “Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche,” *Stem Cells*, vol. 26, no. 8, pp. 2042–2051, 2008.

[56] L. M. Calvi, G. B. Adams, K. W. Weibruch et al., “Osteoblastic cells regulate the haematopoietic stem cell niche,” *Nature*, vol. 425, no. 6960, pp. 841–846, 2003.

[57] J. M. Weber, S. R. Forsythe, C. A. Christianson et al., “Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells,” *Bone*, vol. 39, no. 3, pp. 485–493, 2006.

[58] B. R. Chitteti, Y. H. Cheng, B. Potet et al., “Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function,” *Blood*, vol. 115, no. 16, pp. 3239–3248, 2010.

[59] F. Arai, A. Hirao, M. Ohmura et al., “Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche,” *Cell*, vol. 118, no. 2, pp. 149–161, 2004.

[60] R. S. Taichman, “Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche,” *Blood*, vol. 105, no. 7, pp. 2631–2639, 2005.

[61] S. Stier, Y. Ko, R. Forkert et al., “Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size,” *Journal of Experimental Medicine*, vol. 201, no. 11, pp. 1781–1791, 2005.

[62] N. D. Staudt, W. K. Aicher, H. Kalbacher et al., “Cathepsin X is secreted by human osteoblasts, digests CXCL12 and impairs adhesion of hematopoietic stem and progenitor cells to osteoblasts,” *Haematologica*, vol. 95, no. 9, pp. 1452–1460, 2010.

[63] A. P. D. N. de Barros, C. M. Takiya, R. Garzoni et al., “Osteoblasts and bone marrow mesenchymal stromal cells control hematopoietic stem cell migration and proliferation in 3D in vitro model,” *PLoS ONE*, vol. 5, no. 2, Article ID e9093, 2010.

[64] Y. Nakamura, F. Arai, H. Iwasaki et al., “Isolation and characterization of endosteal niche cell populations that regulate hematopoietic stem cells,” *Blood*, vol. 116, no. 9, pp. 1422–1432, 2010.

[65] L. Zhang, C. Niu, L. Ye et al., “Identification of the hematopoietic stem cell niche and control of the niche size,” *Nature*, vol. 425, no. 6960, pp. 836–841, 2003.

[66] J. Zhu, R. Garrett, Y. Jung et al., “Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cell,” *Blood*, vol. 109, no. 9, pp. 3706–3712, 2007.

[67] D. Visnjic, Z. Kalajzic, D. W. Rowe, V. Katavic, J. Lorenzo, and H. L. Aguila, “Hematopoeisis is severely altered in mice with an induced osteoblast deficiency,” *Blood*, vol. 103, no. 9, pp. 3258–3264, 2004.

[68] M. J. Kiel, G. L. Radice, and S. J. Morrison, “Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance,” *Cell Stem Cell*, vol. 1, no. 2, pp. 204–217, 2007.

[69] H. Kobayashi, J. M. Butler, R. O’Donnell et al., “Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of hematopoietic stem cells in a mouse chronic inflammatory arthritis model,” *Blood*, vol. 114, no. 20, pp. 4402–4410, 2009.

[70] M. J. Kiel, M. Aclar, G. L. Radice, and S. J. Morrison, “Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance,” *Cell Stem Cell*, vol. 4, no. 2, pp. 170–179, 2009.

[71] B. Li, A. S. Bailey, S. Jiang, B. Liu, D. C. Goldman, and W. H. Fleming, “Endothelial cells mediate the regeneration of hematopoietic stem cells,” *Stem Cell Research*, vol. 4, no. 1, pp. 17–24, 2010.

[72] A. B. Salter, S. K. Meadows, G. G. Muramoto et al., “Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo,” *Blood*, vol. 113, no. 9, pp. 2104–2107, 2009.

[73] H. Kobayashi, J. M. Butler, R. O’Donnell et al., “Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of hematopoietic stem cells,” *Nature Cell Biology*, vol. 12, no. 11, pp. 1046–1056, 2010.

[74] M. G. Kharas, R. Okabe, J. J. Ganis et al., “Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice,” *Blood*, vol. 115, no. 7, pp. 1406–1416, 2010.

[75] A. T. Hooper, J. M. Butler, D. J. Nolan et al., “Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells,” *Cell Stem Cell*, vol. 4, no. 3, pp. 263–274, 2009.
D. C. Goldman, A. S. Bailey, D. L. Pfaffle, A. Al Masri, J. L. Christian, and W. H. Fleming, "BMP4 regulates the hematopoietic stem cell niche," *Blood*, vol. 114, no. 20, pp. 4393–4401, 2009.

D. C. Goldman, A. S. Bailey, D. L. Pfaffle, A. Al Masri, J. L. Christian, and W. H. Fleming, "BMP4 regulates the hematopoietic stem cell niche," *Blood*, vol. 114, no. 20, pp. 4393–4401, 2009.

C. Durand, C. Robin, K. Bollerot, M. H. Baron, K. Ottersbach, and E. Dzieryzak, "Embryonic stromal clones reveal developmental regulators of definitive hematopoietic stem cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 52, pp. 20838–20843, 2007.

M. Bhatia, D. Bonnet, D. Wu et al., "Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells," *Journal of Experimental Medicine*, vol. 189, no. 7, pp. 1139–1148, 1999.

[106] M. Braun, M. Wunderlin, K. Spieh, W. Knöchel, P. Gierschik, and B. Moepps, "Xenopus laevis stromal cell-derived factor 1: conservation of structure and function during vertebrate development," *Journal of Immunology*, vol. 168, no. 5, pp. 2340–2347, 2002.

[107] H. Zheng, G. Fu, T. Dai, and H. Huang, "Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1α/CXCR4 via PI3K/Akt/eNOS signal transduction pathway," *Journal of Cardiovascular Pharmacology*, vol. 50, no. 3, pp. 274–280, 2007.

[108] D. J. Ceradini, A. R. Kulkarni, M. J. Callaghan et al., "Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1," *Nature Medicine*, vol. 10, no. 8, pp. 858–864, 2004.

[109] Y. Yang, G. Tang, J. Yan et al., "Cellular and molecular mechanism regulating blood flow recovery in acute versus gradual femoral artery occlusion are distinct in the mouse," *Journal of Vascular Surgery*, vol. 48, no. 6, pp. 1546–1558, 2008.

[110] J. L. Christian, and W. H. Fleming, "BMP4 regulates the hematopoietic stem/progenitor cells, " *Blood*, vol. 115, no. 12, pp. 2391–2396, 2010.

[111] V. C. Broudy and K. Kaushansky, "Thrombopoietin, the c-mpl ligand, is a major regulator of platelet production," *Journal of Leukocyte Biology*, vol. 57, no. 5, pp. 719–725, 1995.

[112] N. Debili, F. Wendling, D. Cosman et al., "The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets," *Blood*, vol. 85, no. 2, pp. 391–401, 1995.

[113] O. Livnah, E. A. Stura, S. A. Middleton, D. L. Johnson, L. K. Jolliffe, and I. A. Wilson, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," *Science*, vol. 283, no. 5404, pp. 987–990, 1999.

[114] J. G. Drachman and K. Kaushansky, "Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 6, pp. 2350–2355, 1997.

[115] B. A. Witthuhn, E. W. Quelle, O. Silvennoinen et al., "JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin," *Cell*, vol. 74, no. 2, pp. 227–236, 1993.

[116] P. J. Tortolani, J. A. Johnston, C. M. Bacon et al., "Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2," *Blood*, vol. 85, no. 12, pp. 3444–3451, 1995.

[117] H. Yoshihara, F. Arai, K. Hosokawa et al., "Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche," *Cell Stem Cell*, vol. 1, no. 6, pp. 685–697, 2007.

[118] H. Qian, N. Buza-Vidas, C. D. Hyland et al., "Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells," *Cell Stem Cell*, vol. 1, no. 6, pp. 671–684, 2007.

[119] A. Bersenev, C. Wu, J. Bal cercak, and W. Tong, "Link controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2," *Journal of Clinical Investigation*, vol. 118, no. 8, pp. 2832–2844, 2008.

[120] A. Rongvaux, T. Willinger, H. Takizawa et al., "Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 6, pp. 2378–2383, 2011.

[121] Y. Gomei, Y. Nakamura, H. Yoshihara et al., "Functional differences between two Tie2 ligands, angiiopoietin-1 and -2, in regulation of adult bone marrow hematopoietic stem cells," *Experimental Hematology*, vol. 38, no. 2, pp. 82.e1–89.e1, 2010.

[122] J. J. Trowbridge, M. P. Scott, and M. Bhatia, "Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 38, pp. 14134–14139, 2006.

[123] C. Zhao, A. Chen, C. H. Jamieson et al., "Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia," *Nature*, vol. 458, no. 7239, pp. 776–779, 2009.

[124] A. Merchant, G. Joseph, Q. Wang, S. Brennan, and W. Matsui, "Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors," *Blood*, vol. 115, no. 12, pp. 2391–2396, 2010.

[125] I. Hofmann, E. H. Stover, D. E. Cullen et al., "Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis," *Cell Stem Cell*, vol. 4, no. 6, pp. 559–567, 2009.
[134] J. Gao, S. Graves, U. Koch et al., “Hedgehog signaling is dispensable for adult hematopoietic stem cell function,” Cell Stem Cell, vol. 4, no. 6, pp. 548–558, 2009.

[135] S. Artavanis-Tsakonas, M. D. Rand, and R. J. Lake, “Notch signaling: cell fate control and signal integration in development,” Science, vol. 284, no. 5415, pp. 770–776, 1999.

[136] G. L. Lin and K. D. Hankenson, “Integration of BMP Wnt, and Notch signaling pathways in osteoblast differentiation,” Journal of Cellular Biochemistry, vol. 112, no. 12, pp. 3491–3501, 2011.

[137] P. Ranganathan, K. L. Weaver, and A. J. Capobianco, “Notch signalling in solid tumours: a little bit of everything but not all the time,” Nature Reviews Cancer, vol. 11, no. 5, pp. 338–351, 2011.

[138] K. Ohishi, B. Varnum-Finney, and I. D. Bernstein, “Delta-1 enhances marrow and thymus repopulating ability of human CD34+CD38− cord blood cells,” Journal of Clinical Investigation, vol. 110, no. 8, pp. 1165–1174, 2002.

[139] B. Varnum-Finney, L. M. Halasz, M. Sun, T. Gridley, F. Radtke, and I. D. Bernstein, “Notch2 governs the rate of generation of mouse long- and short-term repopulating stem cells,” Journal of Clinical Investigation, vol. 121, no. 3, pp. 1207–1216, 2011.

[140] B. Varnum-Finney, C. Brashem-Stein, and I. D. Bernstein, “Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability,” Blood, vol. 101, no. 5, pp. 1784–1789, 2003.

[141] S. Stier, T. Cheng, D. Dombkowski, N. Carlesso, and D. T. Scadden, “Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome,” Blood, vol. 99, no. 7, pp. 2369–2378, 2002.

[142] J. M. Rowlinson and M. Gering, “Hey2 acts upstream of Notch in hematopoietic stem cell specification in zebrafish embryos,” Blood, vol. 116, no. 12, pp. 2046–2056, 2010.

[143] I. Maillard, U. Koch, A. Dumortier et al., “Canonical notch signaling is dispensable for the Maintenance of adult hematopoietic stem cells,” Cell Stem Cell, vol. 2, no. 4, pp. 356–366, 2008.

[144] S. J. C. Mancini, N. Mantei, A. Dumortier, U. Suter, H. R. MacDonald, and F. Radtke, “Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation,” Blood, vol. 105, no. 6, pp. 2340–2342, 2005.

[145] Y. W. Kim, B. K. Koo, H. W. Jeong et al., “Defective Notch activation in microenvironment leads to myeloproliferative disease,” Blood, vol. 112, no. 12, pp. 4628–4638, 2008.

[146] M. Santaguida, K. Schepers, B. King et al., “JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal,” Cancer Cell, vol. 15, no. 4, pp. 341–352, 2009.

[147] W. K. Clements, A. D. Kim, K. G. Ong, J. C. Moore, N. D. Lawson, and D. Traver, “A somitic Wnt16/Notch pathway specifies haematopoietic stem cells,” Nature, vol. 474, no. 7350, pp. 220–224, 2011.

[148] R. B. Chalamalasetty, W. C. Dunty Jr., K. K. Biris et al., “The Wnt3a/β-catenin target gene Mesogenin1 controls the segmentation clock by activating a Notch signalling program,” Nature Communications, vol. 2, no. 1, article 390, 2011.

[149] S. Han, N. Dzedzic, P. Gadue, G. M. Keller, and V. Gouon-Evans, “An endothelial cell niche induces hepatic specification through dual repression of Wnt and notch signaling,” Stem Cells, vol. 29, no. 2, pp. 217–228, 2011.

[150] I. S. Peter and E. H. Davidson, “A gene regulatory network controlling the embryonic specification of endoderm,” Nature, vol. 474, no. 7353, pp. 635–639, 2011.

[151] D. W. Kim, J. S. Lee, E. S. Yoon, B. I. Lee, S. H. Park, and E. S. Dhong, “Influence of human adipose-derived stromal cells on Wnt signaling in organotypic skin culture,” Journal of Craniofacial Surgery, vol. 22, no. 2, pp. 694–698, 2011.

[152] N. Sato, L. Meijer, L. Skaltsounis, P. Greengard, and A. H. Brivanlou, “Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor,” Nature Medicine, vol. 10, no. 1, pp. 55–63, 2004.

[153] P. S. Woll, J. K. Morris, M. S. Fainschab et al., “Wnt signaling promotes hematopoietic cell development from human embryonic stem cells,” Blood, vol. 111, no. 1, pp. 122–131, 2008.

[154] C. H. Wu and R. Nusse, “Ligand receptor interactions in the Wnt signaling pathway in Drosophila,” Journal of Biological Chemistry, vol. 277, no. 44, pp. 41762–41769, 2002.

[155] H. C. Wong, A. Bourdelas, A. Krauss et al., “Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled,” Molecular Cell, vol. 12, no. 5, pp. 1251–1260, 2003.

[156] N. S. Tobiwinski, M. Wehli, A. Rives, N. Erdeniz, S. Dinardo, and E. Wieschaus, “Wg/Wnt signal can be transmitted through arrow/lrp5.6 and axin independently of Zw3/Gsk3β activity,” Developmental Cell, vol. 4, no. 3, pp. 407–418, 2003.

[157] T. Kramps, O. Peter, E. Brunner et al., “Wnt/Wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear β-catenin-TCF complex,” Cell, vol. 109, no. 1, pp. 47–60, 2002.

[158] M. Katoh and M. Katoh, “Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico,” International Journal of Molecular Medicine, vol. 12, no. 4, pp. 643–649, 2003.

[159] J. R. Miller, A. M. Hocking, J. D. Brown, and R. T. Moon, “Mechanism and function of signal transduction by the Wnt/B-catenin and Wnt/Ca2+ pathways,” Oncogene, vol. 18, no. 55, pp. 7860–7872, 1999.

[160] M. N. Chamorro, D. R. Schwartz, A.onica, A. H. Brivanlou, K. R. Cho, and H. E. Varmus, “FGF-20 and DKK1 are transcriptional targets of β-catenin and FGF-20 is implicated in cancer and development,” The EMBO Journal, vol. 24, no. 1, pp. 73–84, 2005.

[161] D. Pennica, T. A. Swanson, J. W. Welsh et al., “WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 25, pp. 14717–14722, 1998.

[162] T. C. He, A. B. Sparks, C. Rago et al., “Identification of c-MYC as a target of the APC pathway,” Science, vol. 281, no. 5382, pp. 1509–1512, 1998.

[163] O. Tetsu and F. McCormick, “β-catenin regulates expression of cyclin D1 in colon carcinoma cells,” Nature, vol. 398, no. 6726, pp. 422–426, 1999.

[164] J. A. Kim, Y. J. Kang, G. Park et al., “Identification of a stroma-mediated Wnt/β-catenin signal promoting self-renewal of hematopoietic stem cells in the stem cell niche,” Stem Cells, vol. 27, no. 6, pp. 1318–1329, 2009.
[165] T. C. Luis, F. Weerkamp, B. A. E. Naber et al., "Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation," *Blood*, vol. 113, no. 3, pp. 546–554, 2009.

[166] M. Scheller, J. Huelsken, F. Rosenbauer et al., "Hematopoietic stem cell and multilineage defects generated by constitutive β-catenin activation," *Nature Immunology*, vol. 7, no. 10, pp. 1037–1047, 2006.

[167] P. Kirstetter, K. Anderson, B. T. Porse, S. E. W. Jacobsen, and C. Nerlov, "Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block," *Nature Immunology*, vol. 7, no. 10, pp. 1048–1056, 2006.

[168] J. J. Trowbridge, A. Xenocostas, R. T. Moon, and M. Bhatia, "Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation," *Nature Medicine*, vol. 12, no. 1, pp. 89–98, 2006.

[169] H. E. Fleming, V. Janzen, C. Lo Celso et al., "Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo," *Cell Stem Cell*, vol. 2, no. 3, pp. 274–283, 2008.

[170] K.-H. Ko, T. Holmes, P. Palladinetti et al., "GSK-3β inhibition promotes engraftment of ex vivo-expanded hematopoietic stem cells and modulates gene expression," *Stem Cells*, vol. 29, no. 1, pp. 108–118, 2011.

[171] M. Kinder, C. Wei, S. G. Shelat et al., "Hematopoietic stem cell function requires 12/15-lipoxygenase-dependent fatty acid metabolism," *Blood*, vol. 115, no. 24, pp. 5012–5022, 2010.